Ephedra “Template” Will Increase Scrutiny Of Labeling, AERs – Israelsen
This article was originally published in The Tan Sheet
Executive Summary
FDA's ban of ephedrine alkaloid-containing dietary supplements will have a definitive impact on supplement labeling going forward, according to Utah Natural Products Alliance Executive Director Loren Israelsen
You may also be interested in...
Ephedra Ban Effective In April; FDA Will Follow-Up On Internet Firms
A 1final rule prohibiting the sale of dietary supplements containing ephedrine alkaloids will become effective April 12, FDA announced Feb. 6
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands